241 related articles for article (PubMed ID: 8772805)
1. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
[TBL] [Abstract][Full Text] [Related]
2. The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine.
Yokel RA; Meurer KA; Skinner TL; Fredenburg AM
Drug Metab Dispos; 1996 Jan; 24(1):105-11. PubMed ID: 8825197
[TBL] [Abstract][Full Text] [Related]
3. Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity.
Yokel RA; Meurer KA; Hong CB; Dickey KM; Skinner TL; Fredenburg AM
Drug Metab Dispos; 1997 Feb; 25(2):182-90. PubMed ID: 9029049
[TBL] [Abstract][Full Text] [Related]
4. Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine.
Yokel RA
J Toxicol Environ Health; 1994 Feb; 41(2):131-74. PubMed ID: 8301696
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of potential aluminum chelators in vitro by aluminum solubilization ability, aluminum mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminum.
Yokel RA; Datta AK; Jackson EG
J Pharmacol Exp Ther; 1991 Apr; 257(1):100-6. PubMed ID: 2019981
[TBL] [Abstract][Full Text] [Related]
6. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease.
Savory J; Huang Y; Wills MR; Herman MM
Neurotoxicology; 1998 Apr; 19(2):209-14. PubMed ID: 9553957
[TBL] [Abstract][Full Text] [Related]
7. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
Navarro JA; Granadillo VA; Rodríguez-Iturbe B; García R; Salgado O; Romero RA
Clin Nephrol; 1991 May; 35(5):213-7. PubMed ID: 1855329
[TBL] [Abstract][Full Text] [Related]
8. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
[TBL] [Abstract][Full Text] [Related]
9. Desferrioxamine in the treatment of aluminum overload.
Ackrill P; Day JP
Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
[TBL] [Abstract][Full Text] [Related]
10. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
Vogelsang U
Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
[TBL] [Abstract][Full Text] [Related]
11. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
12. The effect of desferrioxamine on tissue aluminum concentration and bone histology in aluminum-loaded rats with renal failure.
Verbeelen D; Smeyers-Verbeke J; van Hooff I; de Roy G
J Trace Elem Electrolytes Health Dis; 1988 Jun; 2(2):67-72. PubMed ID: 2980801
[TBL] [Abstract][Full Text] [Related]
13. Effect of the chelator desferrioxamine on aluminum elimination in rabbits.
Melograna JM; Yokel RA
Res Commun Chem Pathol Pharmacol; 1983 Jun; 40(3):497-509. PubMed ID: 6622822
[TBL] [Abstract][Full Text] [Related]
14. Clinical and histological results of long-term management of aluminium overloading in uraemic patients with desferrioxamine.
Canavese C; Pacitti A; Segoloni G; Thea A; D'Amicone M; Stratta P; Rossi P; Sabbioni E; Pietra R; Constantini S
J Trace Elem Electrolytes Health Dis; 1989 Mar; 3(1):17-23. PubMed ID: 2535315
[TBL] [Abstract][Full Text] [Related]
15. Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered?
Savory J; Exley C; Forbes WF; Huang Y; Joshi JG; Kruck T; McLachlan DR; Wakayama I
J Toxicol Environ Health; 1996 Aug; 48(6):615-35. PubMed ID: 8772802
[TBL] [Abstract][Full Text] [Related]
16. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
17. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
Wang G; Zhu P; Wang S
Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
[TBL] [Abstract][Full Text] [Related]
18. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.
McLachlan DR; Smith WL; Kruck TP
Ther Drug Monit; 1993 Dec; 15(6):602-7. PubMed ID: 8122302
[TBL] [Abstract][Full Text] [Related]
19. Effects of subchronic desferrioxamine infusion on aluminum toxicity in rabbits.
Melograna JM; Yokel RA
Res Commun Chem Pathol Pharmacol; 1984 Jun; 44(3):411-22. PubMed ID: 6463364
[TBL] [Abstract][Full Text] [Related]
20. Combined chelation based on glycosyl-mono- and bis-hydroxypyridinones for aluminium mobilization: solution and biodistribution studies.
Chaves S; Dron PI; Danalache FA; Sacoto D; Gano L; Santos MA
J Inorg Biochem; 2009 Nov; 103(11):1521-9. PubMed ID: 19748126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
